Skip to main content

Clinical Trials Using Ipilimumab

Review the clinical trials studying ipilimumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 77

Neoadjuvant Anti-PD-L1 Immunotherapy for the Treatment of Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
NC410 in Combination with Nivolumab and FOLFIRINOX Chemotherapy, with or without Ipilimumab, for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status: Active
Location: 2 locations
Ipilimumab in Combination with Relatlimab and Nivolumab for the First Line Therapy in Patients with Stage III-IV Unresectable or Metastatic Melanoma, TRINITY Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Inulin Gel in Combination with Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Nivolumab and Hydroxychloroquine or Nivolumab, Ipilimumab, and Hydroxychloroquine for the Treatment of Stage III-IV Melanoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
iExosomes in Combination with Ipilimumab for the Treatment of Patients with Metastatic Pancreas Cancer with KrasG12D Mutation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Split Course Adaptive Radiation Therapy and Immunotherapy with or without Chemotherapy for the Treatment of Stage IV or Locally Advanced Lung Cancer, SiCARIO Study
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Nivolumab and Ipilimumab with and without Camu Camu for the Treatment of Patients with Metastatic Renal Cell Carcinoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
CBL0137 in Combination with Ipilimumab and Nivolumab for the Treatment of Stage III-IV Metastatic, Unresectable, or Recurrent Melanoma
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab for the Treatment of Stage II-III Melanoma
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
A Pooled Mutant KRAS-Targeted Long Peptide Vaccine in Combination with Nivolumab and Ipilimumab for the Treatment of Locally Advanced, Unresectable or Metastatic KRAS Mutated Non-small Cell Lung Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
RNA-Lipid Particle Vaccine for the Treatment of Early Melanoma Recurrence after Anti-PD-1 Antibody Therapy
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Zanzalintinib in Combination with Ipilimumab and Nivolumab for the Treatment of Metastatic or Unresectable Refractory Soft Tissue Sarcoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Intralesional Influenza Vaccine for the Treatment of Stage I-III and IV Melanoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells with or without Nivolumab and Ipilimumab in Treating Patients with Recurrent or Refractory Glioblastoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
FLC Peptide Vaccine Combined with Nivolumab and Ipilimumab for the Treatment of Patients with Fibrolamellar Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Status: Active
Location: See ClinicalTrials.gov
Risk-Adapted, Proteomic-Guided (PROphet CB, and CARG-TT) Systemic Therapy for the Treatment of Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer
Status: Approved
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Immunotherapy (Nivolumab and Ipilimumab) with and without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Status: Approved
Location: 2 locations
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy with or without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients who are PD-L1 Negative
Status: Temporarily Closed to Accrual
Location: 156 locations
Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Status: Temporarily Closed to Accrual
Location: 424 locations
Nivolumab and/or Ipilimumab with or without Azacitidine in Treating Patients with Myelodysplastic Syndrome
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas